BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
08/13/2021
Initial Lawsuit
08/13/2021
Lawsuit Progression
11/08/2021
Dismissal
01/12/2022
Investigation regarding Yalla’s public statements about its user metrics, revenue and second quarter 2021 financial results.
08/09/2021
Yalla releases its Q2 2021 financial results: quarterly revenues come in short ($66.62 million) of analysts’ expectations. The company discloses an increase of 19.5% to 6.4 million of paying users from 5.4 million in Q2 2020. The number of paying users previously grew 233% from 1.62 million during Q1 2020 to Q2 2020.
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$9.41 | $9.4 | $0.01 | 0.11% |
Plaintiff brings this securities class action on behalf of Plaintiff and all other persons or entities, except for Defendants, who purchased or otherwise acquired Yalla American Depository Shares (ADSs) between September 30, 2020 and August 9, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) the Company overstated its user metrics and revenue and,
(ii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
11/08/2021
The court issued an order appointing the lead plaintiff and lead counsel.
On 01/12/2022, plaintiff voluntarily dismissed the complaint.
Counsel for Lead Plaintiffs Peifa Xu and Yongjun Li (“Plaintiffs”) and counsel for Defendants Yalla Group Limited and Tao Yang (the “Defendants,” and together with Plaintiffs, the “Parties”) have conferred and stipulate to the relief requested in this motion.
[…]
WHEREAS, Plaintiffs have elected not to file the Amended Complaint or pursue this Action any further;.
WHEREAS, Defendants deny that they engaged in any wrongful acts or are liable on any of the claims asserted in this Action;
Free File
Stipulation/Order of Dismissal
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.